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year overall survival rate was 55.5%.
Conclusions: In our experience, ASCT was associated with
excellent disease control and outcomes in patients with











Number 76 12 40
Median age (range) 54 (16-72) 52 (22-72) 55 (26-70)
Conditioning
Regimen:
Melphalan 41 (54%) 5 (42%) 25 (62%)
Myeloablative
chemotherapy
35 (46%) 7 (58%) 15(38%)
Autologous Stem
Cell Source:
Peripheral blood 68 (89%) 12 (100%) 39 (98%)
Bone marrow 6 (8%) 0 0
Both 2 (3%) 0 1 (2%)
Bortezomib use:
Prior to transplant 10 (13%) 5 (42%) 15 (38%)
Post transplant 5 (7%) 0 5 (12%)152
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Busulfan (Bu) is commonly used with cyclophosphamide
(Cy) as a conditioning regimen for HPCT. We previously re-
ported that substituting IV for oral Bu was associated with
less relapses and superior relapse free (RFS) and overall
survivals (OS) for relapsed or refractory NHL pts undergoing
AHPCT (Br J Haematol 2010;148:226-34). It is unknown
whether such a beneﬁt exists for IV Buwhen usedwith Cy for
AHPCT for plasma cell myeloma.We performed a prospective
studywith this regimenwithout Bu dose adjustment in order
to compare outcomes with historical controls who received
oral Bu at our institution. 55 pts were transplantedwith IV Bu
from 7/29/09-8/23/12 and 117 oral Bu pts were transplanted
from 3/22/94-4/6/06. IV Bu pts were older (P < 0.001), more
often had lower Karnofsky PS at HPCT (P< 0.001), more prior
therapies (P < 0.001), more advanced disease status at HPCT
(p¼0.002) and a longer median time from diagnosis to HPCT
(14 vs 8 mos, P < 0.001). More oral Bu pts received G-CSF
alone for mobilization therapy (90 vs 46%, P < 0.001), had
more days of apheresis (median 3 vs 2, P< 0.001) and higher
median CD34+ and TNC doses (7.22 vs 4.68 x 106/kg,
respectively, P< 0.001; 12.60 vs. 8.52 x 108/kg, respectively, P
< 0.001). There were no differences in time to neutrophil
engraftment, but platelet engraftment was more rapid for
oral Bu pts (median 11 vs 15 d, P < 0.001). Oral Bu pts had
signiﬁcantly more and worse mucositis by the modiﬁed
OMAS (66% vs. 0%, P < 0.001; median scores 0.2 vs. 0, P <
0.001). IV Bu pts had more infections (p¼0.034), but there
were no differences between the groups regarding CMV
infection, GI or pulmonary toxicity, relapse, relapse free
survival RFS or OS. At this time 46 (84%) of the IV Bu and 39
(33%) of the oral Bu pts are alive, however, the median follow
up was longer for the oral Bu pts (118 vs 13 mos, P < 0.001).
The median RFS and OS have not yet been observed in the IV
Bu group, but were 26 and 63 months, respectively for the
oral Bu pts. Disease relapse was the most common cause of
death for both the IV and oral Bu pts (67% and 77% of deaths).
1 and 2 year relapse mortality rates were 7% and 19% for IV
Bu pts and 7% and 22% for oral Bu pts. 1 and 2 year non-
relapse mortality rates were 5% and 12% for IV Bu and 4% and
4% for oral Bu. Death due to pulmonary toxicity occurred in 4
oral Bu pts and 0 IV Bu pts. Based upon these preliminary
results using IV instead of oral Bu decreases toxicity and
potentially improves safety as suggested from our ﬁnding of
signiﬁcantly less oral mucositis and no pulmonary deaths
with IV Bu. Further follow up of the IV Bu pts is required to
adequately assess for a survival beneﬁt. Investigation of PK
based Bu dosing strategies in this transplant setting may be
appropriate to help elucidate whether outcomes may be
further improved.153
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Introduction: Varicella-Zoster Virus (VZV) infection is
a relatively common cause of morbidity following autologous
hematopoietic cell transplant (auto-HCT). Previous guide-
lines recommended antiviral prophylaxis against VZV only
during the post HCT neutropenia period. The CDC in 2009
recommended extending VZV prophylaxis for 1 year post-
transplantation.
Methods:We retrospectively analyzed rates of VZV infection
following auto-HCTat our transplant center prior to and after
the implementation of extended acyclovir prophylaxis in
June 2008. We divided our study population into three
different cohorts according to the length of VZV prophylaxis:
(1) prophylaxis until neutrophil recovery to 500/uL (n¼76),
(2) prophylaxis for 6months (n¼12) or (3) 12months (n¼40)
post auto-HCT. All patients received acyclovir 400 mg oral or
iv twice daily or valacyclovir 500 mg oral daily. For patients
in whom VZV infection occurred, data was collected on
severity of infection, timing of onset, treatment of the reac-
tivation and any associated complications.
Results: 128 patients undergoing auto-HCT between January
1,2004 and January 31, 2010were included in the study. Table
1 demonstrates baseline characteristics for the three cohorts.
By Fisher's exact test, there was a signiﬁcant difference in
rates of VZV infection between the neutrophil recovery and
12months prophylaxis cohorts at 14% (n¼11) and 2% (n¼1)
(P¼0.03), respectively. VZV infection rate in the 6months
prophylaxis groupwas 16% (n¼2), but did not reach statistical
signiﬁcance due to small numbers. Median time to the onset
of VZV infection was 4 months (1-10 months) in the neutro-
phil recovery group, whereas only 1 event occurred in the 12
month prophylaxis group at 19-months post-transplant.
Complications observed with VZV infections include post-
Abstracts / Biol Blood Marrow Transplant 19 (2013) S178eS193 S191herpetic neuralgia (n¼5), severe pain (n¼3), scarring (n¼1),
and motor weakness (n¼1); 2 patients required hospitaliza-
tion and 3 patients developed disseminated zoster.
Conclusions: Our limited retrospective analysis suggests
a signiﬁcant reduction in rates of post auto-HCT rates of VZV
infection with extended 12month antiviral prophylaxis. VZV
infection is a signiﬁcant complication post auto-HCT, and
extended prophylaxis appears to be safe and effective in this
setting.
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High Dose Melphalan and Autologous Stem Cell
Transplantation for Systemic AL Amyloidosis e Single
Institute Analysis of 35 Casese
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We report 35 patients who received high dose melphalan
and autologous stem cell transplantation for systemic AL
amyloidosis. Between Sep. 2006 and Jul. 2012, 35 patients
with AL amyloidosis were transplanted at Japanese Red Cross
Medical Center. Characteristics of patients were shown as
follows: median age; 54 (range 39-70), M/F¼15/20, major
organ involvement; heart 13, kidney 19, others 3 (liver 1,
trachea 1, peripheral nerve 1), median melphalan dose; 128
(range 50-200) mg/m2, median infused CD34+ cells; 2.67
(range 1.17-11.26) x 106/kg. Out of 35 patients, 28 are alive
after median follow up of 18.7 (range 2-68) months and two
and four years estimated overall survival were 84.6% and
66.6%, respectively. Four patients died of heart failure and
other three patients died of either gastrointestinal bleeding,
bacteremia, or malignancy. Four year estimated survival of
patients with cardiac involvement is 46.2% and is signiﬁ-
cantly lower as compared with that with others (69.2%).
Serum albumin increased (average 21%) in patients survived
more than 12months after ASCT. Serum free light chain (FLC)
was measured before and after ASCT in 7 patients, and of
those, FLC rapidly decreased after ASCT in 5 patients. Patients
without cardiac involvement showed satisfactory survival
with improvement of clinical symptom and serum albumin.
Careful patient selection and experienced management are
important especially for patients with cardiac involvement.
Serum FLCmay be useful for evaluating effectiveness of ASCT
and also for early detection of relapse.155
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Background: The use of plerixafor formobilization following
chemotherapy has not been extensively studied. We tested
the hypothesis that adding plerixafor to G-CSF after chemo-
therapywould increase the proportion of patientsmobilizing
the target number of hematopoietic progenitor cells in one
day to 75% from a historical value of 50%.Methods:Multiplemyeloma (MM) or lymphoma patients for
whom autologous stem cell transplantation was intended
were eligible. Patients were mobilized with chemotherapy
consisting of either cyclophosphamide (N¼16), DCEP (N¼1),
R-ICE (N¼10), CHOP (N¼2) or R-HyperCVAD (N¼5) with daily
administration of G-CSF at a dose of 10 mcg/kg/day starting
one day after the completion of chemotherapy. The per-
protocol plan was subcutaneous injection of 240 mcg/kg
plerixaforon theﬁrstdayonwhich theneutrophil countwas>
1500 cells/uL followed by apheresis the next day. G-CSF, pler-
ixafor and apheresis were repeated daily until 5 (lymphoma)
or 10 x 10E6 CD34+ cells/kg (myeloma) were collected.
Results: 17 MM and 28 lymphoma patients with a median
age of 57 (range 33-73) were enrolled. 33/45 subjects (76%)
collected the target number of CD34+ cells in one day. 12
subjects (7 MM and 5 lymphoma) with a median CD34+
count of 201 cells/uL began apheresis without plerixafor on
the ﬁrst day of monitoring and collected a median of 19 x
10E6 CD34+ cells/kg in one day. The remaining 33 patients
(10 MM and 23 lymphoma) received plerixafor with median
numbers of 30 CD34+ cells/uL, and 4100 neutrophils/uL that
increased to 95 CD34+ cells/uL and 24,799 neutrophils/uL the
next day. Plerixafor-treated subjects collected amedian of 7.8
x 10E6 CD34+ cells/kg; 22 (66%) collected the target number
in one day, while 6 (18%), 3 (9%), and 2 (6%) of the plerixafor-
treated subjects required 2, 3, or 4 days of apheresis,
respectively. Plerixafor was well tolerated, with 29 total AE,
and no SAE recorded during mobilization and/or apheresis.
Seven grade 3/4 AE were seen, including thrombocytopenia
(4), fatigue (1), anemia (1) and hypokalemia (1). 44/45
enrolled subjects underwent high-dose chemotherapy and
re-infusion of CD34+ cells. Plerixafor-treated and non-pler-
ixafor treated transplant recipients promptly engrafted with
neutrophil and platelets at median of 12 and 16 days,
respectively, with stable hematopoiesis noted at 12 months.
Conclusions: Plerixafor administration after chemotherapy
for ASC mobilization is feasible and well tolerated. A greater
percentage (76%) of enrolled subjects collected more than
the target number of cells in one day of apheresis compared
with a historical cohort of patients mobilized with G-CSF
after chemotherapy (54%; P < 0.03). Daily monitoring of
blood counts after chemotherapy is needed to appropriately
schedule plerixafor administration. One-fourth of chemo-
therapy-treated patients mobilized an adequate number of
CD34+ in one day without plerixafor.156
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Bone marrow is a highly innervated tissue with nerve ﬁbers
terminating in association with stromal cells. Bone marrow
neuropathy has been associated with abnormal hematopoi-
etic stem cell (HSC) trafﬁcking and activity in animal models
of diabetes. There is also evidence that granulocyte colony-
stimulating factor (G-CSF) mediates its mobilizing effect on
HSC through modulation of norepinephrine release from
adrenergic neurons. Therefore, we hypothesized that pre-
